Carl Zeiss Meditec Full Year 2023 Earnings: EPS Beats Expectations

Carl Zeiss Meditec (ETR:AFX) Full Year 2023 Results

Key Financial Results

• Revenue: €2.09b (up 9.8% from FY 2022).
• Net income: €290.4m (down 1.2% from FY 2022).
• Profit margin: 14% (down from 15% in FY 2022). The decrease in margin was driven by higher expenses.
• EPS: €3.25 (down from €3.29 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Carl Zeiss Meditec EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%.

Looking ahead, revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany.

Performance of the German Medical Equipment industry.

The company's shares are up 14% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Carl Zeiss Meditec's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.